Download PDF version
(a printed version will be available in the conference bag)

15:00Opening Welcome Desk
16:00Welcome ceremony
in the presence of grand-children and great-grandchildren of Jules Bordet, discoverer of Bordetella pertussis.
Welcome address by Prof. Oberdan Leo, Vice-Rector of the Université Libre de Bruxelles. The work of Jules Bordet, as it is remembered 100 years after the Nobel Prize.
Mrs. Nathalie Devroey, Great-granddaughter of Jules Bordet. A portrait of Jules Bordet as a person.
16:30James D. Cherry – University of California, USA
The 112-years odyssey of pertussis and pertussis vaccines – mistakes made and implications for the future.
17:00Special opening session
on Adenylate Cyclase Toxin in honour of Erik Hewlett
17:00Damron F. HeatWest Virginia University, USA
For the love of ACT
17:20Hewlett Erik – University of Virginia, USA
The saga of Bordetella adenylate cyclase toxin: how did we get here and where are we going?
17:50Ladant Daniel Institut Pasteur, France
The adenylate cyclase toxin form Bordetella pertussis: a jack of many trades.
18:10Sebo Peter – Institute of Microbiology, Czech Academy of Sciences, Czech Republic
The why and what for of Bordetella pertussis adenylate cyclase toxin.

Welcome reception at the Museum of Medicine

08:00Opening Welcome Desk
9:00Session 1: Clinical and epidemiological aspects of pertussis
Chair: K. Edwards & J. Cherry
9:00Klein Nicola – Kaiser Permanente Vaccine Study Center, USA
Evolving pertussis epidemiology: impact of a mature acellular pertussis vaccine program.
9:30Read Robert – University of Southampton, UK
A human controlled infection model of Bordetella pertussis colonisation.
10:00Campbell HelenPublic Health England, UK
An update on the maternal pertussis immunization programme in England.
10:20Marshall HelenThe University of Adelaide, Australia
Severe hospitalized pertussis and effectiveness of maternal vaccination against severe pertussis in infants aged <6 months
10:40Coffee break
11:00Edmunds MattPublic Health England, UK
Evaluation of symptomatic and asymptomatic transmission of Bordetella pertussis during an outbreak in a secondary boarding school, England, 2018.
11:20Raeven Rene – intravacc, The Netherlands
Immunoproteomic profiling of Bordetella pertussis infection-induced responses reveals distinct antibody responses between human individuals with different pertussis immunization background.
11:40Fry NormanPublic Health England, UK
External quality assessment for the detection of Bordetella pertussis by PCR in Europe.
12:00Walking Lunch & poster viewing
14:00Session 2: Bordetella biology and pathogenesis
Chair: R. Fernandez & M.E. Rodriguez
14:00Merkel Tod – Food and Drug Administration, USA
Pertussis pathogenesis and transmission: insights from the baboon model.
14:30Jacob-Dubuisson Françoise – Center for Infection and Immunity of Lille, France
Copper homeostasis in Bordetella pertussis in relation with pathogenesis.
15:00Naninck Thibaut CEA, France
In vivo imaging of B. pertussis colonization and interactions with the host by probe-based confocal laser endomicroscopy in the baboon respiratory tract.
15:20Ernst Katharina Ulm University Medical Center, Germany
Intoxication of mammalian cells with pertussis toxin is impaired by pharmacological cyclophilin inhibitors.
15:40Coffee break
16:00Scanlon KarenUniversity of Maryland, USA
Developmentally regulated angiotensin system potentiates severe manifestations of disease in an infant mouse model of pertussis.
16:20Ifill GylesThe University of British Columbie, Canada
Altered RNA turnover in Bordetella pertussis provides insight into regulatory RNAs implicated in pathogenesis.
16:40MacArthur IainUniversity of Bath
Mutations in Bordetella pertussis acr cause sensitivity to hydrophobic molecules and fatty acids.
17:00Chen QingFood and Drug Administration, USA
Both RisA and RisR response regulators are required for the activation of Bvg-repressed vrgs in Bordetella pertussis.
17:20Poster viewing & fresh drinks
9:00Session 3: Immunity and Vaccination
Chair: N. Carbonetti & F. Mascart
9:00Mills Kingston – Trinity College Dublin, Ireland
Mechanism of sustained natural and vaccine-induced protective immunity against nasal colonization with Bordetella pertussis.
9:30Cartelle Gestal Monica – University of Georgia, USA
Immunomodulation suppresses innate and adaptive immunity to Bordetella infection.
09:50Kroes Michel – RIVM, The Netherlands
Activation of human NK cells by Bordetella pertussis requires inflammasome activation in macrophages.
10:10Mionnet Cyrille – Ciml Immunology, France
Pertussis toxin is critical to generate tissue resident memory T cell populations in the lung of Bordetella pertussis infected mice.
10:30Coffee break
11:00Hozbor DanielaUniversida Nacional de La Plata, Argentina
Outer membrane vesicles as vaccine candidates against infections caused by different species of Bordetella genus.
11:30Da Silva Antunes Ricardo – La Jolla Institute for Immunology, USA
Differences in T cell responses to Bordetella pertussis in adults as a function of whole cell versus acellular childhood vaccination.
11:50Kapil Parul – FDA, USA
Polarization of acellular pertussis vaccine-primed immune responses to the Th17 response.
12:10Ardanuy Jeremy – University of Maryland, USA
Type I and III interferons exacerbate lung immunopathology during Bordetella pertussis infection.
12:30Boehm Dylan – West Virginia University, USA
Intranasal pertussis vaccine inhibits pathogenesis of Bordetella pertussis at the site of infection.
12:50Walking Lunch & poster viewing
14:30Session 3: Immunity and Vaccination – cont.
Chair: N. Carbonetti & F. Mascart
14:30Locht CamilleInstitut Pasteur de Lille, France
Development of the live attenuated BPZE1 pertussis vaccine.
15:00Lin Ang Karolinska Institutet, Sweden
Characterization of the immune responses in humans generated to the live Bordetella pertussis vaccine BPZE1.
15:20Abu-Raya Bahaa – BC Children’s Hospital Research Inst., Canada
Immunizations in infants born to women immunized with pertussis-containing vaccines in pregnancy versus unimmunized women: systematic review and meta-analysis.
15:40Maynard Jennifer – The University of Texas at Austin, USA
Anti-pertussis toxin humanized monoclonal antibodies provide pertussis prophylaxis in newborn baboons.
16:00Poster viewing & fresh drinks
17:30Discussion about the Bordetella Society
19:30Banquet at The Belgian Comic Strip Center
9:00Session 4: Evolutionary and Genomic aspects of Bordetella
Chair: E.T. Harvill & F.H. Damron
9:00Preston AndrewUniversity of Bath, UK
The hidden genome of Bordetella pertussis.
9:30He QiushuiUniversity of Turku, Finland
Surveillance of circulating Bordetella pertussis strains in Europe.
10:00Rohani Pejman – University of Georgia, USA
Epidemiology and evolution of pertussis in the Netherlands.
10:20Weigand Michael – CDC, USA
wgMLST scheme development and validation for improved molecular typing of Bordetella pertussis.
10:40Coffee break
11:00Session 5: Bordetellae other than Bordetella pertussis in human and veterinary medicine
Chair: D. Hozbor & C. Locht
11:00Harvill Eric – University of Georgia, USA
Emergence of Bordetella species as pathogens.
11:30Nicholson Tracy – USDA, USA
Contribution of the BvgR and RisAS regulons in Bordetella bronchiseptica biology.
12:00Yount Kacy – The Ohio State University College of Medicine, USA
An acellular vaccine containing BcfA a an antigen and the sole adjuvant protects mice against laboratory and clinical isolates of Bordetella bronchiseptica.
12:20Gu Xin-Xing – NIH, USA
NIAID/NIH funding resources for Bordetella research & product development.
12:30Round-table discussion: G. Renauld-Mongénie – F.H. Damron
Short- and long-term solutions for the control of pertussis and other Bordetella diseases.
13:30Closure Lunch
Close Menu
dapibus mattis venenatis non neque. ipsum justo leo diam